Associate Professor Jing-Ke Weng of the Whitehead Institute and MIT is the recipient of a $1 million grant from the W. M. Keck Foundation to develop new biotechnologies that enable directed evolution of metabolic enzymes at will. If successful, this project will have a transformative impact upon multiple fields by enabling the unprecedented capability to create new designer medicines and commodity chemicals.
